Backs FY24 revenue view $2.7B-$2.8B, consensus $2.76B. Backs FY24 adjusted EBITDA $610M-$630M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- AMRX Earnings this Week: How Will it Perform?
- Amneal Pharmaceuticals receives FDA approval of Pyridostigmine Bromide NDA
- Amneal Pharmaceuticals price target raised to $12 from $10 at Truist
- Amneal and Metsera Partner to Target Obesity Market
- Amneal Pharmaceuticals and Metsera to codevelop weight loss medicines